

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098676699US, in an envelope addressed to: Box DAC, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: June 27, 2002

Signature

*Linda A. Bourg*  
(Linda A. Bourg)

Docket No.: P02490US0  
(PATENT)

#7 A  
m.m.  
12/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Neill B. Walsdorf, Sr. et al.

Application No.: 09/919,025  
Filed: July 31, 2001

Group Art Unit: 1616

Examiner: R. M. DeWitty

FOR CALCIUM GLUTARATE SUPPLEMENT AND  
PHOSPHORUS BINDER

Box Non Fee  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

RECEIVED  
JUL 02 2002  
OFFICE OF PETITIONS

Applicants submit the following amendments and remarks in response to the Action, mailed November 15, 2001, in the above-identified matter, as part of the Petition to Revive Unintentionally Abandoned Application, filed under 37 C.F.R. 1.137(b), submitted herewith. Applicants respectfully request entry of this submission and the amendments provided herein.

**In the Specification:**

Please enter the following amendments to the specification, as indicated below in clean form by paragraph, to correct typographical and grammatical errors to the instant application.

**1. Page 8, first paragraph:**

A primary aim of prophylactic and therapeutic measures in patients with renal osteodystrophy is therefore to lower the level of serum phosphate below a threshold value of 1.8 mmol/l (5.6 mg phosphorus/dl). A dietary restriction of the phosphate intake and thereby an effective lowering of the level of serum phosphate is limited if not impossible in long-term therapy since there is the risk of an inadequate protein intake and thus of malnutrition. Thus for example on an average dietary phosphate intake of 3.8 to 4.7 g/day only about 1 g phosphate per day can be eliminated by dialysis (hemodialysis or peritoneal dialysis). Thus